Medical Writing Patient-reported outcomes Publication planning and patient-reported outcomes: Demonstrating value in a multi-stakeholder era

Volume 27, Issue 4 - Patient-reported outcomes

Publication planning and patient-reported outcomes: Demonstrating value in a multi-stakeholder era


Patient-reported outcomes (PROs) are an essential element to demonstrate the value of a health intervention. In many ways, PROs represent the ultimate “real-world” data, yet the drive towards “Big Data” has focused on
routinely collected data from healthcare databases, which often do not include assessments of PROs or the patient voice. Effective planning of PRO publications requires an in-depth understanding of the planned
studies, the opportunities these provide for publications, and how clinicians, patients, and caregivers may contribute as authors to provide validation of results. Mainstream clinical journals and conferences should be targeted wherever possible, considering the availability and objectives of “enhanced publication” options and open access to increase reach, comprehension, and impact. PRO publications must be written in a clear and engaging way, explaining the instrument in simple terms, and addressing the “so what?” question – ideally with an accompanying plain language summary. And PRO publications must always thank the patients.

Download the full article


  1. United States Government. Clinical trials registration and results information submission. Final rule [Internet]. 2016 [cited 2018 Sep 6]. Available from: Available from: s/2016/09/21/2016–22129/clinicaltrials- registration-and-results-informationsubmission.
  2. European Commission. Commission Guideline – Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. 2012 [cited 2018 Sep 6]. Available from: Available from: health//sites/health/files/files/eudralex/ vol-10/2012_302–03/2012_302–03_en. pdf.
  3. White R, Willett J, Field P. HEOR: why it is changing the world of medical publications. The MAP newsletter [Internet]. 2017 [cited 2018 Sep 6]. Available from: Available from: 14/heor-why-it-is-changing-the-world-ofmedical- publications/.
  4. Vakil NB, Halling K, Becher A, Ryden A. Systematic review of patient-reported outcome instruments for gastroesophageal reflux disease symptoms. Eur J Gastroenterol Hepatol. 2013;25(1):2–14. 10.1097/MEG.0b013e328358bf74. Available from: http://
  5. Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, et al. Development of the GerdQ, a tool for the diagnosis and management of gastrooesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30(10):1030–8. 10.1111/j.1365– 2036.2009.04142.x. Available from: http://
  6. Jones R, Coyne K, Wiklund I. The gastrooesophageal reflux disease impact scale: a patient management tool for primary care. Aliment Pharmacol Ther. 2007;25(12):1451–9. 10.1111/j.1365– 2036.2007.03343.x. Available from: http://
  7. Mitchell P, Bressler N, Tolley K, Gallagher M, Petrillo J, Ferreira A, et al. Patientreported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmol. 2013;131(10):1339– 47. 10.1001/jamaophthalm01.2013.4592. Available from: http://
  8. Kay S, Ferreira A. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores. Ophthalmic Epidemiol. 2014;21(2):66–78. 10.3109/09286586.2014.888456. Available from: http://
  9. Hongo M, Kinoshita Y, Shimozuma K, Kumagai Y, Sawada M, Nii M. Psychometric validation of the Japanese translation of the Quality of Life in Reflux and Dyspepsia questionnaire in patients with heartburn. J Gastroenterol. 2007;42(10):807–15. 10.1007/ s00535–007–2098–9. Available from: http://
  10. Talley NJ, Wiklund I. Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures. Qual Life Res. 2005;14(1):21–33. Available from: http://
  11. Chassany O, Shaheen NJ, Karlsson M, Hughes N, Ryden A. Systematic review: symptom assessment using patientreported outcomes in gastroesophageal reflux disease and dyspepsia. Scand J Gastroenterol. 2012;47(12):1412–21. 10.3109/00365521.2012.712999. Available from: http://
  12. Nagy P, Hage A, Coghill DR, Caballero B, Adeyi B, Anderson CS, et al. Functional outcomes from a head-to-head, randomised, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder and an inadequate response to methylphenidate. Eur Child Adolesc Psychiatry. 2016;25(2):141–9. 10.1007/s00787–015–0718–0. Available from: http://
  13. Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014;14:220. 10.1186/s12883–014–0220–1. Available from: http://
  14. Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, et al. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. J Neurol Sci. 2016;365:190–8. 10.1016/j.jns.2016.03.024. Available from: http://
  15. Bakhai A, Sandberg A, Mittendorf T, Greiner W, Oberdiek AM, Berto P, et al. Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord. 2013;13:108. 10.1186/1471–2261–13–108. Available from: http://
  16. Fridman M, Banaschewski T, Sikirica V, Quintero J, Erder MH, Chen KS. Caregiver perspective on pediatric attention-deficit/ hyperactivity disorder: medication satisfaction and symptom control. Neuropsychiatr Dis Treat. 2017;13:443– 55. 10.2147/NDT.S121639. Available from: http://
  17. Muller-Lissner S, Tack J, Feng Y, Schenck F, Specht Gryp R. Levels of satisfaction with current chronic constipation treatment options in Europe – an internet survey. Aliment Pharmacol Ther. 2013;37(1):137– 45. 10.1111/apt.12124. Available from: http://
  18. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. 10.1038/npjpcrm.2014.9. Available from: http://
  19. Ryden A, Martin M, Halling K, Niklasson A. Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study. Patient. 2013;6(4):307–14. 10.1007/s40271–013–0024–1. Available from: http://
  20. Price DB, Roman-Rodriguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–81 e9. 10.1016/ j.jaip.2017.01.004. Available from: http://
  21. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018;319 (5):483–94. 10.1001/ jama.2017.21903. Available from: http://
  22. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. [cited 2018 Sep 6]. Available from: Available from: icmje-recommendations.pdf.
  23. Kantor D, Bright JR, Burtchell J. Perspectives from the patient and the healthcare professional in multiple sclerosis: social media and participatory medicine. Neurol Ther. 2018;7(1):37–49. 10.1007/s40120–017–0088–2. Available from: http://
  24. Kantor D, Bright JR, Burtchell J. Perspectives from the patient and the healthcare professional in multiple sclerosis: social media and patient education. Neurol Ther. 2018;7(1):23–36. 10.1007/s40120–017–0087–3. Available from: http://
  25. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–22. 10.1001/jama.2013.879. Available from: http://
  26. Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22(6):1161–75. 10.1007/ s11136–012–0252–1. Available from: http://
  27. International Society For Pharma co - economics and Outcomes Research. Good practices for outcomes research. 2018 [cited 2018 Sep 6]. Available from: Available from: good-practices-for-outcomes-research.
  28. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245–51. 10.1097/ACM.0000000000000388. Available from: http://
  29. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6): 349–57. 10.1093/intqhc/mzm042. Available from: http://
  30. European Medicines Agency. Summaries of clinical trial results for laypersons. 2018 [cited 2018 Sep 6]. Available from: Available from: files/files/eudralex/vol-10/2017_01_26_ summaries_of_ct_results_for_ laypersons.pdf.



Patient reported outcomes
President's Message
Measuring health outcomes: The foundation of contemporary healthcare decision-making
Measuring quality of life – theoretical background
Quality of life measures – an overview
Publication planning and patient-reported outcomes: Demonstrating value in a multi-stakeholder era
Patient-reported outcome measure translation: An overview
Systematic hospital collection of patient-reported outcome data via patient apps
The PROMIS of electronic patient-reported outcomes
Interview with Professor Matthias Rose on developing patient-reported outcomes and the PROMIS initiative
The UK pharmaceutical industry braces for Brexit, be it mild, severe, or doomsday
Awareness of medical writing as a profession and its career prospects
Estimands – closing the gap between study design and analysis
Protecting the rights of clinical trial patients through disclosure: The significance of plain language
News from the EMA
Regulatory Matters & Regulatory Public Disclosure
Medical Communications
Medical Devices
Journal Watch
In the Bookstores
Good Writing Practice
Getting Your Foot In The Door
My First Medical Writing
Out on Our Own


The Write Stuff Archive Contact Instructions for Authors Article Template (Word) Journal Policies

Editoral Board


Raquel Billiones


Evguenia Alechine

Jonathan Pitt

Managing Editor

Victoria White

Deputy Managing Editor

Alicia Brooks Waltman

Associate Editors

Anuradha Alahari

Jennifer Bell

Nicole Bezuidenhout

Claire Chang

Barbara Grossman

Sarah Milner

John Plant

Sampoorna Rappaz

Amy Whereat

Section Editors

Daniela Kamir


Jennifer Bell


Nicole Bezuidenhout 

Digital Communication

Somsuvro Basu

EMWA News 

Ana Sofia Correia 

Gained in Translation

Ivana Turek

Getting Your Foot in the Door

Wendy Kingdom / Amy Whereat

Good Writing Practice

Alison McIntosh 

In the Bookstores

Maria Kołtowska-Häggström

Lingua Franca and Beyond

Maddy Dyer


Lisa Chamberlain-James

Medical Communications/Writing for Patients

Payal Bhatia

Medical Devices

Evguenia Alechine

My First Medical Writing

Anuradha Alahari

News from the EMA

Adriana Rocha


Tiziana von Bruchhausen


Clare ChangZuo Yen Lee 

Regulatory Matters

Sam Hamilton

Regulatory Public Disclosure

Claire Gudex

Teaching Medical Writing

Louisa Ludwig-Begall / Sarah Kabani

The Crofter: Sustainable Communications

Louisa Marcombes

Veterinary Writing

Editors Emeritus

Elise Langdon-Neuner

Phil Leventhal

Layout Designer

Chris Monk